Opsoklonus Miyoklonus Sendromu ve Diğer Paraneoplastik Hastalıklar
Özet
Opsoklonus miyoklonus sendromu (OMS), genellikle nöroblastom gibi tümörlerle ilişkili veya enfeksiyöz tetikleyiciler sonucu gelişen, opsoklonus, miyoklonus ve ataksi ile seyreden nadir bir nöroimmünolojik tablodur. Hastalığın patofizyolojisinde otoimmün mekanizmaların ve T/B hücre aktivasyonunun rolü olduğu düşünülmekte olup, tedavi süreci immün modülatör yaklaşımları içermektedir. OMS'nin yanı sıra limbik ensefalit ve anti-NMDA ensefaliti gibi diğer paraneoplastik nörolojik sendromlar da çocukluk çağında tümör süreçlerine eşlik edebilmektedir. Erken tanı ve tedavi, özellikle nöroblastom varlığında prognoz ve kalıcı nörolojik sekellerin yönetimi açısından büyük önem taşımaktadır.
Referanslar
Kinsbourne M. Myoclonic encephalopathy of infants. J Neurol Neurosurg Psychiatry. 1962;25(3):271-6.
Pike M. Opsoclonus-myoclonus syndrome. Handb Clin Neurol. 2013;112:1209-11.
Brunklaus A, Pohl K, Zuberi SM, de Sousa C. Outcome and prognostic features in opsoclonus-myoclonus syndrome from infancy to adult life. Pediatrics. 2011;128(2):e388-94.
Bataller L, Graus F, Saiz A, Vilchez JJ, Spanish Opsoclonus-Myoclonus Study G. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain. 2001;124(Pt 2):437-43.
Ma GM, Chow JS, Taylor GA. Review of paraneoplastic syndromes in children. Pediatr Radiol. 2019;49(4):534-50.
Pang KK, de Sousa C, Lang B, Pike MG. A prospective study of the presentation and management of dancing eye syndrome/opsoclonus-myoclonus syndrome in the United Kingdom. Eur J Paediatr Neurol. 2010;14(2):156-61.
Pranzatelli MR, Tate ED, McGee NR. Demographic, clinical, and immunologic features of 389 children with opsoclonus myoclonus syndrome: a cross-sectional study. Front Neurol. 2017;8:468.
Matthay KK, Blaes F, Hero B et al. Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. Cancer Lett. 2005;228(1–2):275-82.
Blaes F, Dharmalingam B. Childhood opsoclonus-myoclonus syndrome: diagnosis and treatment. Expert Rev Neurother. 2016;16(6):641-8.
Pranzatelli MR, Tate ED, McGee NR. Multifactorial analysis of opsoclonus-myoclonus syndrome etiology (“Tumor” vs “No tumor”) in a cohort of 356 US children. Pediatr Blood Cancer. 2018;65(8):e27097.
Hero B, Radolska S, Gathof BS. Opsomyoclonus syndrome in infancy with or without neuroblastoma is associated with HLA DRB1 01 (abstract). Ped Blood Cancer 2005:45.
Krasenbrink I, Fühlhuber V, Juhasz-Boess I, et al. Increased prevalence of autoimmune disorders and autoantibodies in parents of children with opsoclonus-myoclonus syndrome (OMS). Neuropediatrics 2007;38(3):114-6.
Wong AM, Musallam S, Tomlinson RD, Shannon P, Sharpe JA. Opsoclonus in three dimensions: oculographic, neuropathologic and modelling correlates. J Neurol Sci. 2001;189(1-2):71-81.
Ramat S, Leigh RJ, Zee DS, Optican LM. What clinical disorders tell us about the neural control of saccadic eye movements. Brain 2007;130(Pt 1):10-35.
Anand G, Bridge H, Rackstraw P, Chekroud AM, Yong J, Stagg CJ, et al. Cerebellar and cortical abnormalities in paediatric opsoclonus-myoclonus syndrome. Dev Med Child Neurol 2015;57(3):265-72.
Oguro K, Kobayashi J, Aiba H, Hojo H. Opsoclonus-myoclonus syndrome with abnormal single photon emission computed tomography imaging. Pediatr Neurol 1997;16(4):334-6.
Mustafa M, Levin J, Schoberl F, Rominger A. Postinfectious Opsoclonus-Myoclonus Syndrome in a 41-Year-Old Patient-Visualizing Hyperactivation in Deep Cerebellar Nuclei by Cerebral [(18) F]-FDG- PET. J Neuroimaging 2015;25(4):683-5.
Antunes NL, Khakoo Y, Matthay KK, et al. Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus. J Pediatr Hematol Oncol 2000;22(4):315–20.
Hero B, Schleiermacher G. Update on pediatric opsoclonus myoclonus syndrome. Neuropediatrics. 2013;44(6):324-9.
Blaes F, Pike MG, Lang B. Autoantibodies in childhood opsoclonus-myoclonus syndrome. J Neuroimmunol 2008;201-202:221-6.
Panzer JA, Anand R, Dalmau J, Lynch DR. Antibodies to dendritic neuronal surface antigens in opsoclonus myoclonus ataxia syndrome. J Neuroimmunol 2015;286:86-92.
Pranzatelli MR, Slev PR, Tate ED, Travelstead AL, Colliver JA, Joseph SA. Cerebrospinal fluid oligoclonal bands in childhood opsoclonus-myoclonus. Pediatr Neurol 2011;45(1):27-33.
Pranzatelli MR, Travelstead AL, Tate ED, Allison TJ, Verhulst SJ. CSF B-cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity. Mov Disord 2004;19(7):770-7.
Pranzatelli MR, Tate ED, McGee NR, Verhulst SJ. CSF neurofilament light chain is elevated in OMS (decreasing with immunotherapy) and other pediatric neuroinflammatory disorders. J Neuroimmunol 2014;266(1-2):75-81.
Fuhlhuber V, Bick S, Kirsten A, Hahn A, Gerriets T, Tschernatsch M, et al. Elevated B-cell activating factor BAFF, but not APRIL, correlates with CSF cerebellar autoantibodies in pediatric opsoclonus-myoclonus syndrome. J Neuroimmunol 2009;210(1-2):87-91.
Pranzatelli MR, Tate ED, McGee NR, Ransohoff RM. CCR7 signaling in pediatric opsoclonus-myoclonus: upregulated serum CCL21 expression is steroid-responsive. Cytokine 2013;64(1):331-6.
Pranzatelli MR, Travelstead AL, Tate ED, Allison TJ, Moticka EJ, Franz DN, et al. B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes. Neurology 2004;62(9):1526-32.
Cooper R, Khakoo Y, Matthay KK, et al.Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the Children's Cancer Group. Med Pediatr Oncol 2001;36(6):623-9.
Bhatia P, Heim J, Cornejo P, Kane L, Santiago J, Kruer MC. Opsoclonus-myoclonus-ataxia syndrome in children. J Neurol. 2022;269(2):750-7.
Blumkin L, Kivity S, Lev D et al. A compound heterozygous missense mutation and a large deletion in the KCTD7 gene presenting as an opsoclonus-myoclonus ataxia-like syndrome. J Neurol 2012;259(12):2590–8.
Ki Pang, Lynch BJ, Osborne JP, Pike MG. Dancing Eye Syndrome associated with spontaneous recoery and normal neurodevelopment. Eur J Ped Neurol. 2010;14(2):178-81.
Plantaz D, Michon J, Valteau-Couanet D, et al; Study of the French Society of Pediatric Oncologists. [Opsoclonus-myoclonus syndrome associated with non-metastatic neuroblastoma. Long- term survival]. Arch Pediatr 2000;7(6):621–628.
Gorman MP. Update on diagnosis, treatment, and prognosis in opsoclonus-myoclonus-ataxia syndrome. Curr Opin Pediatr 2010; 22(6):745-50.
Yiu VW, Kovithavongs T, McGonigle LF, Ferreira P. Plasmapheresis as an effective treatment for opsoclonus-myoclonus syndrome. Pediatr Neurol 2001;24(1):72–74.
Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc 2010;85(9):838–54.
Alavi S. Paraneoplastic neurologic syndromes in children: a review article. Iran J Child Neurol. 2013;7 (3):6-14.
Dalmau J, Rosenfeld MR (2008) Paraneoplastic syndromes of the CNS. Lancet Neurol 2008;7:327-40.
Graus F, Delattre JY, Antoine JC et al (2004) Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 75:1135-40.
Gultekin SH, Rosenfeld MR, Voltz R et al (2000) Paraneoplastic limbic encephalitis: neurological symptoms, immunological find- ings and tumour association in 50 patients. Brain 123:1481–94.
